|
About the Guidance, Documents, Resources category
|
|
0
|
519
|
April 14, 2021
|
|
WHO good manufacturing practices considerations for the prevention and control of nitrosamine contamination in pharmaceutical products
|
|
4
|
1022
|
December 21, 2024
|
|
EMA nitrosamine Q&A Appendix 1 rev.7 published on Dec 13, 2024
|
|
6
|
598
|
December 16, 2024
|
|
Autonomous CPCA Web-based calculator FREE
|
|
31
|
5276
|
December 12, 2024
|
|
🇺🇸 FDA Control of Nitrosamine Impurities in Human Drugs revision2
|
|
38
|
2590
|
December 9, 2024
|
|
🇲🇽 Mexico Q&A Live session streaming
|
|
6
|
321
|
December 5, 2024
|
|
Nitrosamine Mitigation: A Path to Regulatory Compliance
|
|
0
|
274
|
November 22, 2024
|
|
🇲🇽 Mexico Nitrosamine Guide published today
|
|
42
|
2537
|
November 22, 2024
|
|
Methylene Blue NDSRI
|
|
6
|
436
|
November 22, 2024
|
|
New EMA Nitrosamine impurities page
|
|
0
|
364
|
November 21, 2024
|
|
Terbinafine Nitrosamines
|
|
3
|
157
|
November 14, 2024
|
|
NDSRI limit for N-nitroso Ciprofloxacin
|
|
2
|
224
|
November 1, 2024
|
|
FDA Statement on Ritonavir and NITMA
|
|
1
|
205
|
October 29, 2024
|
|
Hexamethyldisilazane (HMDS) can form Nitrosamine Impurity?
|
|
7
|
496
|
October 29, 2024
|
|
N-Nitrosamine drug substance related impurities (NDSRIs) – A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 Da -Pub
|
|
0
|
196
|
October 28, 2024
|
|
Nitroso Betahistine Impurity C
|
|
2
|
114
|
October 28, 2024
|
|
Use of L-cysteine as nitrite scavenging
|
|
6
|
219
|
October 25, 2024
|
|
Selection of Solvent and Positive Control Concentration for Enhanced AMES Test -Pub
|
|
0
|
95
|
October 14, 2024
|
|
Oral Liquid Formulations
|
|
4
|
173
|
October 14, 2024
|
|
🇸🇦 Saudi FDA requesting Nitrosamines Risk Assessments
|
|
5
|
1627
|
October 9, 2024
|
|
Dietary exposure assessment for volatile N-nitrosamines from food and beverages for the U.S. population -Pub
|
|
0
|
107
|
September 18, 2024
|
|
NDMA testing in metformin
|
|
5
|
201
|
September 9, 2024
|
|
Vildaglibtin and Metformin in combinationy
|
|
2
|
526
|
September 8, 2024
|
|
USP - CPCA Nitrosamines Case Study
|
|
7
|
1446
|
August 30, 2024
|
|
Resources to help educate reluctant excipient suppliers?
|
|
7
|
325
|
August 28, 2024
|
|
ICH M7 & Nitrosamines Impurities -Updates
|
|
11
|
2770
|
August 28, 2024
|
|
Seventh European Medicines Agency - Medicines for Europe annual bilateral meeting
|
|
1
|
101
|
August 27, 2024
|
|
Analytical methodologies to detect N-nitrosamine impurities in active pharmaceutical ingredients, drug products and other matrices -Pub
|
|
0
|
236
|
August 27, 2024
|
|
🇧🇷 Guideline for the control of Nitrosamines Rev. 4
|
|
24
|
1455
|
August 21, 2024
|
|
AI for NDSRI by Brazil regulatory
|
|
6
|
819
|
August 7, 2024
|